FDA approves Carvykti for patients with multiple myeloma
US FDA approval based on 98 percent response rate in multiple myeloma patients treated once with Carvykti (ciltacabtagene autoleucel, cilta-cel).
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
